| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/26/2001 | EP1135115A2 Use of sibutramine for the treatment of disorders of the central nervous system secondary to organic impairments |
| 09/26/2001 | EP1135113A1 Treatment of parkinson's disease with oligonucleotides |
| 09/26/2001 | EP1135111A2 Autoadhesive oral transmucosal delivery dosage form |
| 09/26/2001 | EP1135106A1 Sustained release matrix systems for highly soluble drugs |
| 09/26/2001 | EP1135105A2 Method for administering agents to the central nervous system |
| 09/26/2001 | EP0888772B1 Sustained-release metal valproate tablets |
| 09/26/2001 | EP0836591B1 Semicarbazones having cns activity and pharmaceutical preparations containing same |
| 09/26/2001 | EP0773932B1 Benzenesulfonamide derivatives used as bradykinine antagonists |
| 09/26/2001 | CN1314999A Modulating multiple lineage kinase proteins |
| 09/26/2001 | CN1314948A Targeted adenovirus vectors for delivery of heterologous genes |
| 09/26/2001 | CN1314912A Tartrate salt of a sabstituted dipentide as growth hormone secretagogue |
| 09/26/2001 | CN1314910A Adenosine derivatives |
| 09/26/2001 | CN1314906A Salts of paroxetine |
| 09/26/2001 | CN1314905A Muscarinic antagonists |
| 09/26/2001 | CN1314900A Particle-formijng compositions containing fused pyrrolocarbazoles |
| 09/26/2001 | CN1314893A IL-8 receptor antanonists |
| 09/26/2001 | CN1314887A Ester of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2A receptor antagonist MDL 110,907 |
| 09/26/2001 | CN1314882A NAALADase inhibitors useful as pharmaceutical compound and compositions |
| 09/26/2001 | CN1314814A Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperdines)-butylazols in preparation of a medicament for the treamtent of pain |
| 09/26/2001 | CN1314180A Scutellaria root extract with nerve protection and medicinal preparation containing said extract |
| 09/26/2001 | CN1314175A Traditional Chinese medicine composition for curing insomnia |
| 09/26/2001 | CN1314167A Addiction giving up cigarette and its formula |
| 09/26/2001 | CN1314151A Use of AFMK in preparing medicine with free radical cloaning function |
| 09/26/2001 | CN1071760C N-terminally chemically modified protein composition and methods |
| 09/26/2001 | CN1071755C Heterocyclyycarboxamide derivatives and their use as therapeutic agents |
| 09/26/2001 | CN1071753C 7-azabicyclo [2,2,1]-heptane and heptene derivatives as cholinergic receptor ligands |
| 09/26/2001 | CN1071741C O-carbamoyl-phenylalanimol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same |
| 09/26/2001 | CN1071571C Composition comprising a tramadol material and acetaminophen and its use |
| 09/26/2001 | CN1071567C Gargle capable of stopping smoking and its preparing method |
| 09/25/2001 | US6294671 Isoxazolo[4, 5-D]pyrimidines as CRF antagonists |
| 09/25/2001 | US6294661 Compounds |
| 09/25/2001 | US6294585 Treatment of neurodegenerative diseases |
| 09/25/2001 | US6294569 Analgesic at central nervous system in the mammalian subject. also, these compounds are inflammatory pain caused, for example by burns (induced by a contact with heat, acid or the other rheumatism or the like, in the said subject. |
| 09/25/2001 | US6294564 Benzimidazoles and benzoxazoles |
| 09/25/2001 | US6294561 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/25/2001 | US6294557 Analgesic at central nervous system in the mammalian subject. also, these compounds are inflammatory pain caused, for example by burns (induced by a contact with heat, acid or the other rheumatism or the like, in the said subject. |
| 09/25/2001 | US6294556 Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 09/25/2001 | US6294551 N-linked sulfonamides of heterocyclic thioesters |
| 09/25/2001 | US6294541 Purine derivatives having phosphodiesterase IV inhibition activity |
| 09/25/2001 | US6294538 Antidiabetic agents and diabetic neuropathy, treatment with oxidoreductase enzymes |
| 09/25/2001 | US6294533 Calcium channel blockers |
| 09/25/2001 | US6294530 Heterocyclic compounds for nervous system disorders |
| 09/25/2001 | US6294525 Reverse-turn mimetics and methods relating thereto |
| 09/25/2001 | US6294522 Compounds for treatment of cardiovascular disorders |
| 09/25/2001 | US6294517 Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
| 09/25/2001 | US6294383 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| 09/25/2001 | US6294377 Adenoviral vectors of canine origin |
| 09/25/2001 | US6294350 Methods for treating fibroproliferative diseases |
| 09/25/2001 | US6294197 Known to be effective in the treatment of congestive heart failure and reducing blood pressure. |
| 09/25/2001 | US6294171 Methods for treating disease states comprising administration of low levels of antibodies |
| 09/25/2001 | US6294169 Interleukin-1 beta converting enzyme like apoptotic protease-6 |
| 09/25/2001 | CA2214601C Mercapto and seleno derivatives as inhibitors of nitric oxide synthase |
| 09/20/2001 | WO2001069261A2 Proteins, genes and their use for diagnosis and treatment of vascular dementia |
| 09/20/2001 | WO2001069252A1 Methods and compositions for the regulation of vasoconstriction |
| 09/20/2001 | WO2001068888A2 Production of chimeric capsid vectors |
| 09/20/2001 | WO2001068880A2 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 09/20/2001 | WO2001068862A1 Insulin homolog polypeptide zins4 |
| 09/20/2001 | WO2001068860A1 Antibodies to human cd154 |
| 09/20/2001 | WO2001068855A2 Gtp-binding protein gamma-12 subunit |
| 09/20/2001 | WO2001068851A2 Polypeptides and nucleic acids encoding same |
| 09/20/2001 | WO2001068825A1 Human nim1 kinase |
| 09/20/2001 | WO2001068815A1 Embryonic stem cells and neural progenitor cells derived therefrom |
| 09/20/2001 | WO2001068700A2 Regulation of human substance p-like g protein-coupled receptor |
| 09/20/2001 | WO2001068697A2 Methods and compositions for immunoregulation |
| 09/20/2001 | WO2001068678A2 Peptides that selectively bind to expanded polyglutamine repeat domains and methods of use thereof |
| 09/20/2001 | WO2001068653A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | WO2001068652A1 Condensed imidazoles as histamine h3 receptor ligands |
| 09/20/2001 | WO2001068651A1 Condensed imidazoles as histamine h3 receptor ligands |
| 09/20/2001 | WO2001068643A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | WO2001068634A1 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity |
| 09/20/2001 | WO2001068633A1 2-phenylpyran-4-one derivatives |
| 09/20/2001 | WO2001068632A1 Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | WO2001068631A1 Method for the preparation of citalopram |
| 09/20/2001 | WO2001068630A1 Method for the preparation of citalopram |
| 09/20/2001 | WO2001068629A1 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | WO2001068628A1 Method for the preparation of citalopram |
| 09/20/2001 | WO2001068627A1 Crystalline base of citalopram |
| 09/20/2001 | WO2001068619A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | WO2001068614A2 5-substituted arylpyrimidines |
| 09/20/2001 | WO2001068612A2 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 09/20/2001 | WO2001068609A1 1,2,3,4-tetrahydroisoquinoline derivatives |
| 09/20/2001 | WO2001068607A1 Amide compounds and use thereof |
| 09/20/2001 | WO2001068603A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 09/20/2001 | WO2001068592A1 Sulfonamide derivatives |
| 09/20/2001 | WO2001068591A1 Carboxylic acid derivatives as ip antagonists |
| 09/20/2001 | WO2001068570A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068569A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068568A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068235A1 Method for preparing colloidal particles in the form of nanocapsules |
| 09/20/2001 | WO2001068140A2 Opioid formulations |
| 09/20/2001 | WO2001068138A2 Intradermal-penetration agents for topical local anesthetic administration |
| 09/20/2001 | WO2001068137A2 Compositions for regulating memory consolidation |
| 09/20/2001 | WO2001068136A1 Drugs for complications of diabetes and neuropathy and utilization thereof |
| 09/20/2001 | WO2001068120A2 Uses of bombesin receptor 3 |
| 09/20/2001 | WO2001068112A2 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
| 09/20/2001 | WO2001068094A1 Heme oxygenase-1 inducers or induction enhancers |
| 09/20/2001 | WO2001068084A1 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068083A1 Use of comt inhibitors as analgesics |
| 09/20/2001 | WO2001068080A2 Neutral antagonists and use thereof in treating drug abuse |
| 09/20/2001 | WO2001068075A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |